



1621

Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (6-98)
Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	09/845,623	
	Filing Date	April 30, 2001	
	First Named Inventor	Agrawal	
	Group Art Unit	1621	
	Examiner Name	McIntosh, Traviss C.	
Total Number of Pages in This Submission	5	Attorney Docket Number	HYB-004US1 (1006/005)

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Postcard
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Small Entity Statement	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Wayne A. Keown, Ph.D., Reg. No. 33,923
Signature	<i>W. A. Keown</i>
Date	10/31/02

RECEIVED

NOV 08 2002

TECH CENTER 1600/2000

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: 10/31/02			
Typed or printed name	Melanie Legare	Date	10/31/02
Signature	<i>Melanie Legare</i>		

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Attorney Docket No.: HYB-004US1)

PATENTS

#111B
11-12-02
[Signature]

Applicant: Agrawal

Serial No.: 09/845,623

Examiner: McIntosh III, Traviss C.

Filing Date: 30 April 2001

Title: MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED
IMMUNE STIMULATION BY POSITIONAL MODIFICATION
OF NUCLEOSIDES

Group Art Unit: 1621

Assistant Commissioner for Patents
Washington, D.C. 20231

CERTIFICATE UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

10/31/02
Date of Deposit

Melanie Legare
Melanie Legare

REPLY TO THE OFFICE ACTION MAILED 2 OCTOBER 2002

Hon. Assistant Commissioner of Patents:

This communication is responsive to the Office Action mailed 2 October 2002.

Applicants hereby elect the invention of group IV, claims 18-22, without traverse.

RECEIVED

NOV 08 2002


TECH CENTER 1600/2900

✓
In addition, prior to the examination of the above-identified application, please amend claim 18 to read as follows.

- B¹
18. (Amended) A method for inducing an immune response in a mammal, the method comprising administering to the mammal a compound comprising a CpG dinucleotide and an immunomodulatory moiety, wherein G is selected from the group consisting of guanosine, 7-deazaguanosine and inosine, and wherein the compound has greater immunostimulatory effect than a similar compound lacking the immunostimulatory moiety.

Support for this amendment can be found in the specification at page 9. This amendment does not add any new subject matter. No fees are believed to be due with this amendment. If any fees are required, the Patent and Trademark Office is authorized to charge such fees to deposit account number 50-2285. If the Examiner believes that any discussion of this communication would be helpful, he is invited to contact the undersigned attorney by telephone at 781-933-6630.

Respectfully submitted,



Wayne A. Keown, Ph.D.
Registration No. 33,923

Keown & Associates
500 West Cummings Park - Suite 1200
Woburn, MA 01801
781-938-1805 (Telephone)
781-938-4777 (Facsimile)